Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Best Practices Reports | Best Practices in Utilizing Health Outcomes Data for Promotional - Commercial Efforts

Best Practices in Utilizing Health Outcomes Data for Promotional - Commercial Efforts

This study aims to discover and collect best practices in how companies use and review the use of Health Outcomes data in promotional/commercial settings. There is a focus upon on-label, off-label and in-label promotions.

Health Outcomes data has become increasingly important to the success of biotechnology and pharmaceutical companies. This study aims to discover and collect best practices in how companies use and review the use of Health Outcomes data in promotional/commercial settings. There is a focus upon on-label, off-label and in-label promotions.

INDUSTRIES PROFILED Health Care; Pharmaceutical; Biotech; Consulting; Manufacturing; Chemical

COMPANIES PROFILED Abbott; Stiefel; Shire; Schering-Plough; PLIVA Pharmaceuticals; Pfizer; OTSUKA; Ortho Biotech; Merck; MedImmune; Janssen Cilag Pharmaceutical; Impax Pharmaceuticals; Drug Development Insights; GlaxoSmithKline; Gilead Sciences; Ethicon Endo-Surgery Inc.; Esteve; Eisai; 3 MAJ; Boehringer Ingelheim; Biogen Idec; Beckman Coulter; Becton Dickinson; Baxter Healthcare; Anesiva; Alpharma Pharma LLC; Amgen; Allergan

STUDY SNAPSHOT The key topics in this research included:- Structure and Reporting Lines of Authority- Health Outcomes Decisions- Use of Health Outcomes Data Proactively and Retrospectively- Who and How is Health Outcomes Data Utilized with Different Groups- Health Outcomes Review Process and Structure

KEY FINDINGS Health Outcomes Sits Within a Centralized Organization: No structure is perfect, but two-thirds of companies place their Health Outcomes Group as part of a centralized organization. 1. Health Outcomes Remains Conservative in Its Review Approach: All companies tend to have their Health Outcomes data reviewed by groups that include Medical Affairs, Legal and Regulatory, with some input from the Commercial/Marketing groups. For the most part, companies remain consistent in their approach to reviewing data that could be used for promotional purposes.2. Large Pharma Chooses to Review Health Outcomes Data at the Brand Level: All of the Top 20 pharma benchmark partners choose to review data at the brand level. One-third of that group reviews through a centralized group as well as at the therapeutic level.3. With On-Label Data, Companies are Using Data Aggressively for Both Prospective and Retrospective Data: Up to 85 percent of companies are utilizing data on-label with managed Care Account Managers and with Medical Science Liaisons. They also are using data frequently with brand teams.

August 2009, Pages 45 Format PDF
Table of Contents
Table of Contents (PDF)
Price: $3,500.00 / €2,318.05

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions